These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 714324)

  • 1. Oral contraceptive estrogen and plasma lipid levels.
    Hedlin A; Kuksis A; Geher K
    Obstet Gynecol; 1978 Oct; 52(4):430-5. PubMed ID: 714324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen.
    Nash AL; Cornish EJ; Hain R
    Med J Aust; 1979 Sep; 2(6):277-81. PubMed ID: 230411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in plasma lipids caused by oral contraceptives].
    Kaffarnik H
    Z Ernahrungswiss Suppl; 1972; 12():Suppl 12:67-72. PubMed ID: 4114609
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of oral contraceptives on lipoprotein lipids: a prospective study.
    Powell MG; Hedlin AM; Cerskus I; Kakis G; Prudham D; Rosenrot P
    Obstet Gynecol; 1984 Jun; 63(6):764-70. PubMed ID: 6427714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen containing oral contraceptives and antithrombin III activity.
    Rákóczi I; Nagy I; Szigetvári I; Losonczy H; Hadnagy J; Gáti I
    Acta Physiol Acad Sci Hung; 1974; 45(3-4):281-6. PubMed ID: 4471272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on blood lipid and androgen levels of two triphasic oral contraceptives.
    Janaud A; Rouffy J; Upmalis D; Dain MP
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():114-6. PubMed ID: 8260968
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized prospective study of the metabolic effects of four low-estrogen oral contraceptives.
    Briggs MH
    J Reprod Med; 1983 Jan; 28(1 Suppl):92-9. PubMed ID: 6403706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR; Gaspard UJ
    Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term profile of a new progestin.
    Lippman J
    Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term effect of hormonal contraceptives on the behavior of serum lipids].
    Klinger G; Carol W; Hoppe H; Müller B; Bonow A
    Zentralbl Gynakol; 1977; 99(5):271-6. PubMed ID: 194435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives. Modification of estrogen effects by levonorgestrel.
    Sabra A; Bonnar J
    J Reprod Med; 1983 Jan; 28(1 Suppl):85-91. PubMed ID: 6834350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of oral contraceptives on mononuclear cell cholesteryl ester hydrolase activity.
    Hagemenas FC; Yatsu FM; Manaugh LC
    Lipids; 1980 Jan; 15(1):39-44. PubMed ID: 7360009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma lipid and lipoprotein alterations during oral contraceptive administration.
    Sachs BA; Wolfman L; Herzig N
    Obstet Gynecol; 1969 Oct; 34(4):530-5. PubMed ID: 5822679
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of synthetic oestrogens and progestagens in oral contraceptives on bile lipid composition.
    Down RH; Whiting MJ; Watts JM; Jones W
    Gut; 1983 Mar; 24(3):253-9. PubMed ID: 6826111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral: effects of oral contraceptives, pregnancy, and lactation.
    Goldsmith NF; Johnston JO
    J Bone Joint Surg Am; 1975 Jul; 57(5):657-68. PubMed ID: 1150709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
    Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
    Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of cyclic Ovosiston therapy on plasma lipid fractions of free cholesterol, total cholesterol and phospholipid].
    Carol W; Hempel E; Klinger G; Bünnig S
    Endokrinologie; 1970; 57(1):108-14. PubMed ID: 4099595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.